港股市场今日再现创新药板块热潮，其中荣昌生物表现突出，盘中大涨5.14%，引发投资者广泛关注。这一涨势延续了该公司近期的强劲表现，反映出市场对创新药企业的持续看好。
数据显示，荣昌生物近期股价表现抢眼。过去5个交易日，该股已上涨16.41%；近20个交易日更是累计上涨32.88%。这一涨势与整个创新药板块的强势表现相呼应。据东方财富Choice数据，截至6月13日，港股创新药指数年内大涨87.99%，荣昌生物等多只创新药概念股年内涨幅靠前。
值得注意的是，今日早盘荣昌生物出现一笔大宗交易，成交量为250万股，成交价为50.60港元，涉资1.26亿港元。这笔大单交易可能反映出机构投资者对该公司前景的信心。此外，南向资金也显示出对荣昌生物的青睐，6月13日单日增持89.10万股。截至当日收盘，港股通共持有荣昌生物9926.55万股，占流通股的47.59%，显示出内地投资者对该股的持续看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.